Literature DB >> 7693478

An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.

C Bergmann1, S A Stohlmann, M McMillan.   

Abstract

The immunodominant H-2Dd-restricted cytotoxic T lymphocyte (CTL) response to the HIV-1 gp160 envelope glycoprotein maps to a single determinant in the V3 loop, designated p18. Using a series of peptides synthesized on pins we have determined that the minimal core sequence of this determinant required for CTL recognition comprises 8 amino acids (residues 320-327). However, 9mer and 10mer peptides containing this core sequence were more effective than the 8mer peptide at sensitizing Dd-expressing target cells. To analyze the antigenicity of endogenously synthesized p18, minigenes encoding a 10-amino acid determinant (residues 318-327) and a 67-amino acid peptide (residues 281-348; containing the V3 loop) were expressed using vaccinia virus (Vac) recombinants. Both peptides were as effective as wild-type gp160 in their ability to sensitize target cells for lysis by gp160-specific CTL. Immunization of BALB/c mice with Vac recombinants encoding both gp160 peptides elicited gp160-specific CTL. These data demonstrate that both the V3 loop itself and a 10-residue epitope are sufficient to prime CTL in vivo and strongly support the potential use of minigene-encoded CTL epitopes for recombinant vaccines designed to induce protective T cell-mediated immunity against HIV-1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693478     DOI: 10.1002/eji.1830231109

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Differential effects of flanking residues on presentation of epitopes from chimeric peptides.

Authors:  C C Bergmann; L Tong; R Cua; J Sensintaffar; S Stohlman
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

2.  Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.

Authors:  C Lapham; B Golding; J Inman; R Blackburn; J Manischewitz; P Highet; H Golding
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

3.  Virus-specific and bystander CD8 T cells recruited during virus-induced encephalomyelitis.

Authors:  Audrey M Chen; Nivedita Khanna; Stephen A Stohlman; Cornelia C Bergmann
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 4.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.

Authors:  Maxim Totrov; Xunqing Jiang; Xiang-Peng Kong; Sandra Cohen; Chavdar Krachmarov; Aidy Salomon; Constance Williams; Michael S Seaman; Ruben Abagyan; Timothy Cardozo; Miroslaw K Gorny; Shixia Wang; Shan Lu; Abraham Pinter; Susan Zolla-Pazner
Journal:  Virology       Date:  2010-07-21       Impact factor: 3.616

6.  Antiviral protective immunity induced by major histocompatibility complex class I molecule-restricted viral T-lymphocyte epitopes inserted in various positions in immunologically self and nonself proteins.

Authors:  G Weidt; W Deppert; S Buchhop; H Dralle; F Lehmann-Grube
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

7.  T-cell immune responses against Env from CRF12_BF and subtype B HIV-1 show high clade-specificity that can be overridden by multiclade immunizations.

Authors:  Daniela C Mónaco; Ana M Rodríguez; María F Pascutti; Mauricio Carobene; Juliana Falivene; Alejandro Gómez; Cynthia Maeto; Gabriela Turk; José L Nájera; Mariano Esteban; M Magdalena Gherardi
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

8.  Co-expression of miRNA targeting the expression of PERK, but not PKR, enhances cellular immunity from an HIV-1 Env DNA vaccine.

Authors:  Adam K Wheatley; Marit Kramski; Marina R Alexander; Jesse G Toe; Rob J Center; Damian F J Purcell
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

9.  Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity.

Authors:  Mitsuo Honda; Rui Wang; Wing-Pui Kong; Masaru Kanekiyo; Wataru Akahata; Ling Xu; Kazuhiro Matsuo; Kannan Natarajan; Howard Robinson; Tedi E Asher; David A Price; Daniel C Douek; David H Margulies; Gary J Nabel
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

10.  Novel mucosal DNA-MVA HIV vaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunity.

Authors:  Cynthia Maeto; Ana María Rodríguez; María Pía Holgado; Juliana Falivene; María Magdalena Gherardi
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.